Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease
ReviewHumansOther animalsWith luteolin (in the single case study cited)
This study tested palmitoylethanolamide together with luteolin (in the single case study cited). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Whether palmitoylethanolamide protects against Alzheimer's disease: preclinical and clinical evidence for its proposed neuroprotective mechanisms.
What the authors reported
Preclinical models show neuroprotective effects of palmitoylethanolamide, particularly micronised and ultramicronised forms. The only clinical evidence cited is a SPECT case study of one person with mild cognitive impairment who improved in cognitive performance after 9 months of ultramicronised PEA with luteolin.
Limits of this study
A narrative review; clinical evidence for Alzheimer's disease rests on animal models and a single case study. Funding and conflicts not stated in the abstract.
Source
PubMed 31396087 · doi:10.3389/fphar.2019.00821
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.